A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial

Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords: Adverse events; Brain cancer; Cannabinoids; Glioblastoma; Nabiximols; Overall survival; Progression free survival; Randomised phase II trial; Sativex; Temozolomide; Tumour
Dates:
  • Published: January 2024
  • Published (online): 15 January 2024
  • Accepted: 22 December 2023
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
Funding Information:
Funder
Grant number
Brain Tumour Charity
Not Known
Bristol Myers Squibb
PRISM
Cancer Research UK Supplier No: 138573
A19121
Cancer Research UK Supplier No: 138573
C7852/A19772
Cancer Research UK Supplier No: 138573
A25447
Cancer Research UK Supplier No: 138573
A23814
NHS Health Technology Assessment
09/91/21
NHS Health Technology Assessment
09/91/21
NHS Health Technology Assessment
09/91/21
Yorkshire Cancer Research Account Ref: 2UOLEEDS
L387
NIHR National Inst Health Research
12/35/07
Depositing User: Symplectic Publications
Date Deposited: 25 Jan 2024 16:04
Last Modified: 25 Jan 2024 16:04
Published Version: http://dx.doi.org/10.1186/s12885-023-11792-4
Status: Published
Publisher: Springer Science and Business Media LLC
Identification Number: 10.1186/s12885-023-11792-4
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics